A long acting injectable formulation based on combination of biodegradable poly(D,L-lactide-co-glycolide) microparticles comprising different PLGA polymers and Tacrolimus. The microparticles may include Tacrolimus, a first polymer and a second polymer, and the first and second polymer may differ from each other. Each of the first and second polymers may be a poly(D,L-lactide-co-glycolide) polymer. Each of the first and second polymers may have an identical lactide to glycolide ratio. Each of the first and second polymers may have a different molecular weight
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
2.
SUSTAINED RELEASE INJECTABLE PHARMACEUTICAL FORMULATION OF LEVOTHYROXINE AND PROCESS FOR PREPARATION THEREOF
A stable sustained release injectable formulation based on poly(D,L-lactide-co-glycolide) microparticles comprising levothyroxine is described. The formulation has a theoretical levothyroxine loading of at least 1.5% w/w. A process for preparing the microparticles is also described. The formulation may be used to control hypothyroidism in adults, congenital hypothyroidism in infants, and acquired hypothyroidism in children.
A61K 31/198 - Alpha-amino-acides, p. ex. alanine ou acide édétique [EDTA]
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
3.
SUSTAINED RELEASE MICROPARTICLES AND PROCESS FOR THE PREPARATION THEREOF
The present invention relates to sustained release microparticle pharmaceutical formulations comprising a hydrophobic drug and a process for the preparation thereof.
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising an antimicrobial agent such as Rifaximin or a pharmaceutical acceptable salt, derivative or polymorph thereof as the active ingredient. It also relates to an innovative process for the preparation thereof.
A61K 9/24 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue en doses unitaires constituées de couches ou feuilletées
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
A61P 1/00 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif
A powder including Valaciclovir or pharmaceutical acceptable salt or derivative thereof and an ion exchange resin. The Valaciclovir is in complex with the ion exchange resin forming Drug-Resin complex (DRC) particles, and each DRC particle comprises hydrogen bonds between the ion exchange resin and a cationic center of Valaciclovir. The ratio of Valaciclovir to the ion exchange resin in the DRC particle is 1:0.5. The powder further includes a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. The powder is configured to be reconstituted with an aqueous diluent as suspension for oral administration.
A process may allow the preparation of one or more viscous pharmaceutical formulations and an apparatus may be configured for implementing such a process. A gellable material may be introduced into one chamber, a vehicle may be introduced in the other and by alternately applying force to each chamber, mixing and homogenization may take place. The internal diameter of the connection equipment of the two chambers may be equal to the outlet internal diameters of the chambers. Each chamber may have different diameter, with the first chamber being larger than the second chamber, so as to allow the process to be executed in a simple and more convenient manner.
A61J 3/00 - Dispositifs ou procédés spécialement conçus pour donner à des produits pharmaceutiques une forme physique déterminée ou une forme propre à leur administration
The present invention relates to a preservative free ophthalmic pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Brimonidine or ophthalmological acceptable salts thereof alone or in combination with a therapeutically effective quantity of Timolol or ophthalmological acceptable salts thereof, to be used for the treatment of ocular hypertension and glaucoma.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention relates to a stable preservative-free Cyclosporine emulsion in the form of eye drops and a process for the manufacturing thereof, packed in a container that ensures stability of the product for the treatment of keratoconjunctivitis sicca.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
9.
SUSTAINED RELEASE INJECTABLE PHARMACEUTICAL FORMULATION OF LEVOTHYROXINE AND PROCESS FOR PREPARATION THEREOF
The present invention relates to a stable sustained release injectable formulation based on poly(D,L-lactide-co-glycolide) microparticles comprising Levothyroxine. It also relates to a process for the preparation of microparticles and use to control hypothyroidism in adults, congenital hypothyroidism in infants and acquired hypothyroidism in children.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Generic pharmaceutical preparation for the treatment of gout; Generic pharmaceutical preparations acting on the central nervous system; Generic pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Generic pharmaceutical preparations for animal skincare; Generic pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Generic pharmaceutical preparations for ocular or intraocular surgery; Generic pharmaceutical preparations for the treatment of heart rhythm disorders; Generic pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Generic pharmaceutical preparations for the treatment of infectious diseases; Generic pharmaceutical preparations for treating allergic rhinitis and asthma; Generic pharmaceutical preparations for treating diabetes; Generic pharmaceutical preparations for treating skin disorders; Generic pharmaceutical preparations for use in chemotherapy; Generic pharmaceutical preparations for use in dermatology; Generic pharmaceutical preparations for use in urology; Generic pharmaceutical preparations for wounds; Generic pharmaceutical preparations, namely, anticoagulants; Generic pharmaceutical preparations, namely, antidepressants; Generic pharmaceutical preparations, namely, appetite suppressants; Generic pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Generic pharmaceutical preparations, namely, a drug delivery system comprising polymer based oral tablets for the continuous release of a wide variety of therapeutic agents; Preparations for destroying parasites; Preparations for destroying vermin; Sanitary preparations for medical use; Self-adhesive dressings; Veterinary preparations, namely, pain relief medication
11.
PHARMACEUTICAL FORMULATION COMPRISING TACROLIMUS, METHOD FOR THE PREPARATION THEREOF AND USE
The present invention relates to a long acting injectable formulation based on combination of biodegradable poly(D,L-lactide-co-glycolide) microparticles comprising different PLGA polymers and Tacrolimus. It also relates to a process for the preparation of microparticles & use thereof.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61P 37/06 - Immunosuppresseurs, p. ex. médicaments pour le traitement du rejet de greffe
12.
SOFT GEL CAPSULE COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR
The present invention relates to a method of manufacturing of an immediate release oral liquid formulation comprising ospemifene. Also relates to a self-emulsifying drug delivery system, a self-microemulsifying drug delivery system and a self-nanoemulsifying drug delivery system for oral administration comprising ospemifene and manufacturing methods thereof. Interestingly, the formulations presented in the invention avoid the need for food intake by the patient in need of such treatment previously required for increased bioavailability of Ospemifene tablet formulations.
The present invention relates to a stable preservative-free Cyclosporine emulsion in the form of eye drops and a process for the manufacturing thereof, packed in a container that ensures stability of the product for the treatment of keratoconjunctivitis sicca.
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
14.
PHARMACEUTICAL COMPOSITION COMPRISING A COMBINATION OF SITAGLIPTIN AND METFORMIN AND METHOD OF PREPARATION THEREOF
The present invention relates to a solid pharmaceutical composition comprising a fixed dose combination of Sitagliptin or a pharmaceutically acceptable salt thereof and Metformin or a pharmaceutically acceptable salt thereof, for oral administration and a process for the preparation thereof. The pharmaceutical composition of the present invention is to be used for the treatment of Type 2 diabetes.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
A61K 31/437 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à cinq chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. indolizine, bêta-carboline
Next, milling of the Drug-Resin complex particles until particle size gets less than 250 μm, and then dry mixing of the Drug-Resin complex particles with excipients to form an internal phase. The excipients of the internal phase comprise a suspending agent and a pH agent, and the suspending agent forms a film around each DRC particle and the film decreases interparticle attraction. Next, mixing the internal phase with excipients of an external phase to form the powder, and then sifting the powder to eliminate any clumps.
The present invention relates to an immediate release stable pharmaceutical formulation for oral administration containing a therapeutically effective quantity of 5-chloro-N-({(5S)-2-oxo-3-[4-(3- oxo-4-morpholinyl)-phenyl]-l,3-oxazolidin-5-yl}-methyl)-2 -thiophenecarboxamide or a pharmaceutically acceptable salt thereof, and a method for the preparation thereof.
The present invention relates to a sustained release composition comprising Tapentadol or a pharmaceutically acceptable salt thereof for oral administration for the treatment of severe chronic pain in adults.
A61K 31/137 - Arylalkylamines, p. ex. amphétamine, épinéphrine, salbutamol, éphédrine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
18.
IMMEDIATE RELEASE SOLID DOSAGE FORM COMPRISING TERIFLUNOMIDE AND METHOD OF PREPARATION THEREOF
The present invention relates to an immediate release stable pharmaceutical formulation for oral administration containing a therapeutically effective quantity of Teriflunomide or a pharmaceutically acceptable salt thereof, and a method for the preparation thereof.
The present invention relates to a sustained release and abuse proof composition comprising Tapentadol or a pharmaceutically acceptable salt thereof for oral administration for the treatment of severe chronic pain in adults.
The present invention relates to a method of manufacturing of a prolonged release solid dispersion formulation comprising Tacrolimus or a pharmaceutically acceptable salt thereof. Furthermore it relates to the manufacturing process of such a dosage form.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
21.
SOLID DOSAGE FORM COMPRISING SITAGLIPTIN AND METHOD OF PREPARATION THEREOF
The present invention relates to a solid dosage form useful for the treatment of Type 2 diabetes. The main objective of the present invention is to provide tablets formulation comprising Sitagliptin or a pharmaceutically acceptable salt thereof that is robust and stable. An effective manufacturing process for the preparation of said tablets is also provided.
The present invention relates to a process for the preparation of viscous pharmaceutical formulations and to an apparatus for implementing the process. A gellable material is introduced into one chamber, a vehicle is introduced in the other and by alternately applying force to each chamber, mixing and homogenization takes place. The internal diameter of the connection equipment of the two chambers is equal to the outlet internal diameters of the chambers. And each chamber is chosen to have different diameter, with the first chamber being larger than the second chamber, so as to allow the process to be executed in a simple and more convenient manner.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 38/00 - Préparations médicinales contenant des peptides
A61P 5/02 - Médicaments pour le traitement des troubles du système endocrinien des hormones hypothalamiques, p. ex. TRH, GnRH, CRH, GRH, somatostatine
A61P 5/04 - Médicaments pour le traitement des troubles du système endocrinien des hormones hypothalamiques, p. ex. TRH, GnRH, CRH, GRH, somatostatine pour réduire, bloquer ou contrarier l'activité des hormones hypothalamiques
A61P 5/08 - Médicaments pour le traitement des troubles du système endocrinien des hormones de l'hypophyse antérieure, p. ex. TSH, ACTH, FSH, LH, PRL, GH pour réduire, bloquer ou contrarier l'activité des hormones de l'hypophyse antérieure
23.
PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION CONTAINING CYCLOSPORINE
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention relates to a preservative free ophthalmic pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Brimonidine or ophthalmological acceptable salts thereof alone or in combination with a therapeutically effective quantity of Timolol or ophthalmological acceptable salts thereof, to be used for the treatment of ocular hypertension and glaucoma.
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
The present invention relates to a novel process for the preparation of Tapentadol and intermediate compound 2R,3R)-3-(-methoxyphenyl)-N,N,2-trimethylpentanamine (compound of formula IIa).
C07C 213/08 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné par des réactions n'impliquant pas la formation de groupes amino, de groupes hydroxy ou de groupes hydroxy éthérifiés ou estérifiés
C07C 217/62 - Composés contenant des groupes amino et hydroxy éthérifiés liés au même squelette carboné ayant des groupes hydroxy éthérifiés liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino reliés au cycle aromatique à six chaînons, ou au système cyclique condensé contenant ce cycle, par l'intermédiaire de chaînes carbonées qui ne sont pas substituées de plus par des atomes d'oxygène liés par des liaisons simples reliés par l'intermédiaire de chaînes carbonées ayant au moins trois atomes de carbone entre les groupes amino et le cycle aromatique à six chaînons ou le système cyclique condensé contenant ce cycle
C07C 215/54 - Composés contenant des groupes amino et hydroxy liés au même squelette carboné ayant des groupes hydroxy liés à des atomes de carbone d'au moins un cycle aromatique à six chaînons et des groupes amino liés à des atomes de carbone acycliques ou à des atomes de carbone de cycles autres que des cycles aromatiques à six chaînons du même squelette carboné avec des groupes amino reliés au cycle aromatique à six chaînons, ou au système cyclique condensé contenant ce cycle par l'intermédiaire de chaînes carbonées qui ne sont pas substituées de plus par des groupes hydroxy reliés par l'intermédiaire de chaînes carbonées ayant au moins trois atomes de carbone entre les groupes amino et le cycle aromatique à six chaînons ou le système cyclique condensé contenant ce cycle
26.
PRESERVATIVE FREE PHARMACEUTICAL COMPOSITION FOR OPHTHALMIC ADMINISTRATION CONTAINING CYCLOSPORINE
The present invention relates to a stable preservative-free Cyclosporine emulsion in the form of eye drops and a process for the manufacturing thereof, packed in a container that ensures stability of the product for the treatment of keratoconjunctivitis sicca.
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
27.
Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population
The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present invention relates to a sustained release and abuse proof composition comprising Tapentadol or a pharmaceutically acceptable salt thereof for oral administration for the treatment of severe chronic pain in adults.
The present invention relates to a sustained release composition comprising Tapentadol or a pharmaceutically acceptable salt thereof for oral administration for the treatment of severe chronic pain in adults.
The present invention relates to a method of manufacturing of a prolonged release solid dispersion formulation comprising Tacrolimus or a pharmaceutically acceptable salt thereof. Furthermore it relates to the manufacturing process of such a dosage form.
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
31.
Preservative free pharmaceutical compositions for ophthalmic administration
The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 47/00 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
The present invention relates to a solid pharmaceutical formulation of Vildagliptin or a pharmaceutically acceptable salt thereof in combination with Metformin or a pharmaceutically acceptable salt thereof, to be used for the treatment of Type2 diabetes.
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of Febuxostat MgO complex to enhance API solubility. It also relates to a process for the preparation thereof
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration containing a therapeutically effective amount of Lingolimod HCl in combination with inorganic salts in order to avoid any interaction with the active ingredient and formation of degradation products. It also relates to a process for the preparation thereof.
The present invention relates to a delayed release pharmaceutical composition comprising a fumaric acid ester such as Dimethyl fumarate in the form of gastro-resistant tablets filled into hard gelation capsule.
The present invention relates to a stable pharmaceutical formulation in the form of tablet for oral administration comprising a therapeutically effective amount of an iron chelating agent, in particular Deferasirox in an amount higher than 60% by weight based on the total weight of the medicament and an effective amount of a non-ionic surfactant. It also relates to a process for the preparation thereof.
The present invention relates to a novel process for the preparation of SGLT-2 inhibitors via addition of a hydroxymethylene group in an open chain intermediate, readily accessible from D-glucose.
C07C 43/18 - Éthers une liaison sur l'oxygène de la fonction éther étant sur un atome de carbone d'un cycle autre que ceux d'un cycle aromatique à six chaînons
C07F 7/18 - Composés comportant une ou plusieurs liaisons C—Si ainsi qu'une ou plusieurs liaisons C—O—Si
C07C 213/00 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné
C07C 213/08 - Préparation de composés contenant des groupes amino et hydroxy, amino et hydroxy éthérifiés ou amino et hydroxy estérifiés liés au même squelette carboné par des réactions n'impliquant pas la formation de groupes amino, de groupes hydroxy ou de groupes hydroxy éthérifiés ou estérifiés
39.
SOFT GEL CAPSULE COMPRISING A SELECTIVE ESTROGEN RECEPTOR MODULATOR
The present invention relates to a method of manufacturing of an immediate release oral liquid formulation comprising ospemifene. Also relates to a self-emulsifying drug delivery system, a self-mircoemulsifying drug delivery system and a self-nanoemulsifying drug delivery system for oral administration comprising ospemifene and manufacturing methods thereof. Interestingly, the formulations presented in the invention avoid the need for food intake by the patient in need of such treatment previously required for increased bioavailability of Ospemifene tablet formulations.
A61K 9/48 - Préparations en capsules, p. ex. de gélatine, de chocolat
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
40.
Process for preparing biodegradable polymers of high molecular weight
A novel method for the preparation of biodegradable polymers is disclosed. The method produces polymers of high molecular weight and particularly allows for stirring throughout the polymerization reaction.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
C08G 63/81 - Procédés de préparation utilisant des solvants
C08G 63/85 - Germanium, étain, plomb, arsenic, antimoine, bismuth, titane, zirconium, hafnium, vanadium, niobium, tantale ou leurs composés
41.
Preservative free pharmaceutical compositions for ophthalmic administration
The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
A61K 31/382 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à six chaînons, p. ex. thioxanthènes
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
The present invention relates to an ophthalmic aqueous composition for the decrease of intraocular pressure in patients with ocular hypertension or open angle glaucoma containing a combination of Brinzolamide and Brimonidine and a method for preparation thereof. The invention as currently presented has a significant advantage over ophthalmic compositions already known in the art. More particularly the present invention relates to a multi-dose ophthalmic aqueous composition comprising a borate, a single polyol and benzalkonium chloride as an antimicrobial agent.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/32 - Composés macromoléculaires obtenus par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. carbomères
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
A61K 31/498 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. quinoxaline, phénazine
A61K 31/542 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec au moins un azote et au moins un soufre comme hétéro-atomes d'un cycle, p. ex. sulthiame condensés en ortho ou en péri avec des systèmes hétérocycliques
The present invention relates to a preservative-free ophthalmic composition for the reduction of elevated intraocular pressure containing Latanoprost or a combination of Latanoprost and Timolol and to a process for preparing such compositions.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
44.
PHARMACEUTICAL COMPOSITION COMPRISING VILDAGLIPTIN AND METHOD OF PREPARATION THEREOF
The present invention relates to a solid pharmaceutical formulation of Vildagliptin to be used for the treatment of Type2 diabetes. The main objective of the present invention is to provide a formulation of Vildagliptin that is stable and robust and the manufacturing process is easy and cost effective.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
45.
PROCESS FOR PREPARING BIODEGRADABLE POLYMERS OF HIGH MOLECULAR WEIGHT
A novel method for the preparation of biodegradable polymers is disclosed. The method produces polymers of high molecular weight and particularly allows for stirring throughout the polymerization reaction.
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
C08G 63/81 - Procédés de préparation utilisant des solvants
C08G 63/82 - Procédés de préparation caractérisés par le catalyseur utilisé
C08G 63/83 - Métaux alcalins, métaux alcalino-terreux, béryllium, magnésium, cuivre, argent, or, zinc, cadmium, mercure, manganèse ou leurs composés
C08G 63/84 - Bore, aluminium, gallium, indium, thallium, métaux des terres rares ou leurs composés
C08G 63/85 - Germanium, étain, plomb, arsenic, antimoine, bismuth, titane, zirconium, hafnium, vanadium, niobium, tantale ou leurs composés
46.
PHARMACEUTICAL COMPOSITION COMPRISING AN ANTIEMETIC AGENT AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of an antiemetic agent in particular Aprepitant and an effective amount of surface stabilizer in order to improve bioavailability. It also relates to a process for the preparation thereof.
The present invention relates to a delayed release pharmaceutical composition comprising a fumaric acid ester such as Dimethyl fumarate in the form of gastro-resistant tablets filled into hard gelation capsule.
The present invention relates to an immediate release stable pharmaceutical formulation comprising a therapeutically effective amount of Prasugrel besylate and an amount of surfactant.
A61K 31/4365 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique ayant le soufre comme hétéro-atome du cycle, p. ex. ticlopidine
49.
PHARMACEUTICAL COMPOSITION COMPRISING A NON-PURINE SELECTIVE INHIBITOR OF XANTHINE OXIDASE AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a non- purine selective inhibitor of xanthine oxidase, in particular Febuxostat and an effective amount of an alkalizing agent. It also relates to a process for the preparation thereof.
The present invention relates to the field of drug delivery and, particularly, to alternative processes for preparing ophthalmic compositions of Brinzolamide or pharmaceutical acceptable salts thereof.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/12 - Acides carboxyliquesLeurs sels ou anhydrides
A61K 47/14 - Esters d’acides carboxyliques, p. ex. acides gras monoglycérides, triglycérides à chaine moyenne, parabènes ou esters d’acide gras de PEG
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 47/44 - Huiles, graisses ou cires couvertes par plus d’un des groupes Huiles, graisses ou cires naturelles ou naturelles modifiées, p. ex. huile de ricin, huile de ricin polyéthoxylée, cire de lignite, lignite, gomme-laque, colophane, cire d’abeille ou lanoline
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
51.
PROCESS FOR PREPARING COMPOUNDS USEFUL AS INTERMEDIATES FOR THE PREPARATION OF RALTEGRAVIR
The invention discloses a novel and selective methylation process used in the preparation of Raltegravir and intermediates. Further disclosed is an improved method for the reaction of intermediate amine compound of formula IIb with oxadiazole intermediate compound of formula V.
C07D 239/557 - Deux atomes d'oxygène liés par une liaison double ou sous forme de radicaux hydroxyle non substitués avec d'autres hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, liés directement aux atomes de carbone du cycle avec des atomes de carbone comportant trois liaisons à des hétéro- atomes, avec au plus une liaison à un halogène, liés directement aux atomes de carbone du cycle, p. ex. acide orotique
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
The present invention relates to a preservative-free ophthalmic composition for the reduction of elevated intraocular pressure containing Latanoprost or a combination of Latanoprost and Timolol and to a process for preparing such compositions.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/5575 - Eicosanoïdes, p. ex. leucotriènes ayant un cycle cyclopentane, p. ex. prostaglandine E2, prostaglandine F2-alpha
A61K 47/34 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p. ex. polyesters, acides polyaminés, polysiloxanes, polyphosphazines, copolymères de polyalkylène glycol ou de poloxamères
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
53.
PHARMACEUTICAL COMPOSITION COMPRISING AN ATYPICAL ANTIPSYCHOTIC AGENT AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to controlled release pharmaceutical formulations comprising an atypical antipsychotic agent such as Paliperidone in the form of capsule filled with mini-tablets that provide zero order drug release. It also relates to a process for the preparation thereof.
A novel process for the preparation of a long acting injectable composition based on biodegradable poly(D,L-lactide-co-glycolide) microspheres comprising peptide active pharmaceutical ingredients.
The present invention relates to a preservative free ophthalmic pharmaceutical formulation for topical administration containing a therapeutically effective quantity of Bimatoprost or ophthalmological acceptable salts thereof and a therapeutically effective quantity of Timolol or ophthalmological acceptable salts thereof, to be used for the treatment of ocular hypertension and glaucoma.
The present invention relates to water dispersible mini-tablets of Enalapril or a pharmaceutically acceptable salt thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined as 0 to 18 years of age. The water dispersible mini-tablets of Enalapril further include a disintegrant, a diluent, a lubricant and a glidant. The active ingredient is distributed evenly in the mini-tablet and the disintegrant comprises Crospovidone. The mini-tablet has a diameter of 3 mm and disintegrates in less than 15 seconds in water.
A61K 31/401 - ProlineSes dérivés, p. ex. captopril
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
B65B 1/00 - Emballage de matériaux solides fluents, p. ex. de poudres, de matériaux fibreux granulés ou en vrac, de masses en vrac de petits objets, dans des réceptacles ou récipients individuels, p. ex. sacs ou sachets, boîtes, cartons, bidons ou pots
B65B 63/02 - Dispositifs accessoires, non prévus ailleurs, opérant sur des objets ou matériaux à emballer pour comprimer ou tasser les objets ou matériaux à emballer avant de les emballer ou de les introduire dans des réceptacles ou récipients
57.
Pediatric powder for oral suspension containing antiviral agent and method for the preparation thereof
The present invention relates to a pediatric powder for reconstitution as suspension for oral administration comprising a therapeutically effective amount of an antiviral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendly product. It also relates to a process for the preparation thereof.
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61J 1/14 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques DétailsAccessoires à cet effet
59.
PHARMACEUTICAL COMPOSITION COMPRISING DARUNAVIR AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to an immediate release pharmaceutical formulation comprising Darunavir. It also relates to a process for the preparation thereof.
A61K 31/635 - Composés contenant des groupes para-N-benzènesulfonyl-N-, p. ex. sulfanilamide, p-nitrobenzènesulfonohydrazide contenant un hétérocycle, p. ex. sulfadiazine
The present invention relates to a novel process for the preparation of tryptamine, its substituted derivatives and intermediates for the preparation of them.
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a triazole antifungal agent or pharmaceutical acceptable salt thereof, in particular Voriconazole and an effective amount of a solubility enhancing agent. It also relates to a process for the preparation thereof.
The present invention relates to controlled release pharmaceutical formulations comprising an atypical antipsychotic agent such as Paliperidone or pharmaceutical acceptable salt thereof in the form of a multi-layer tablet that provides zero order drug release. It also relates to a process for the preparation thereof.
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration containing a therapeutically effective amount of Ivabradine HCl polymorph IV or δ in combination with moisture protective excipients and/or low or non- hygroscopic anhydrous excipients in order to avoid polymorphic transformation of the active ingredient. It also relates to a process for the preparation thereof.
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
64.
PHARMACEUTICAL COMPOSITION CONTAINING AN ECHINOCANDIN ANTIFUNGAL AGENT AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to an aqueous solution comprising an echinocandin antifungal agent such as Caspofungin acetate, as the active ingredient, a buffering agent and at least a diluent/bulking agent. It also relates to the lyophilization of such solution in order to retrieve a dry powder for reconstitution prior to use.
C07K 7/56 - Peptides cycliques contenant au moins une liaison peptidique anormale comportant au moins une liaison peptidique anormale dans le cycle cyclisés autrement que par l'acide diamino-2,4 butanoïque
The present invention relates to a stable pharmaceutical formulation for oral administration comprising a therapeutically effective amount of Atomoxetine or a pharmaceutically acceptable salt or polymorph thereof with an effective amount of a silicon dioxide that improves suspendability of the active pharmaceutical ingredient.
The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
The present invention relates to novel preparation methods for Topiroxostat through novel intermediates comprising novel methods for the formation of the triazole ring and for the cyanation of the pyridyl ring.
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61P 13/00 - Médicaments pour le traitement des troubles du système urinaire
68.
PHARMACEUTICAL COMPOSITION COMPRISING APREPITANT AND METHOD FOR THE PREPARATION THEREOF
Amorphous solid dispersions significantly improve solubility problems associated with Aprepitant. Finished dosage forms as well as processes for the preparation thereof are provided.
The present inventions relates to a solid pharmaceutical dosage form comprising Levodopa/Entacapone/Carbidopa, or pharmaceutically acceptable salts or hydrates thereof, characterized in that the active agents are stabilized with the use of dextrates.
The present invention relates to preparation of biodegradable microparticles formed from polylactide-polyglycolide copolymers (PLGA) polymer and how to achieve sigmoidal release of active pharmaceutical compound from the microparticles. In particular, the present invention relates to emulsification of an inner/oil phase to an outer/water phase followed by quenching and a single drying step for the preparation of microparticles having a preferred release profile of preferably basic/nucleophilic compounds such as risperidone. Alternatively the present invention is also suitable for hydrophobic compounds that have poor water-solubility and a high drug loading of >20% w/w is required. The release profile can be controlled by adjusting the degree of saturation of the outer/water phase with the organic solvent used in the inner/oil phase, the polymer concentration of the inner/oil phase and the temperature at the quenching step. In particular, an initial lag phase and a substantially sigmoidal release profile are achieved by using an outer aqueous phase over saturated with the solvent used in the inner phase at emulsification step, in combination with a low temperature during quenching.
C08J 3/14 - Pulvérisation ou granulation par précipitation à partir de solutions
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
72.
PRESERVATIVE FREE OPHTHALMIC PHARMACEUTICAL COMPOSITION CONTAINING PROPRANOLOL FOR USE IN TREATMENT OF RETINOPATHY OF PREMATURITY AND METHOD OF PREPARATION THEREOF
The present invention relates to a preservative free ophthalmic aqueous composition containing the beta-blocker propranolol or pharmaceutically acceptable salts thereof for the treatment of retinopathy of prematurity in a pediatric population of a specific age and a method for preparation thereof. Moreover, such a preservative-free formulation is packed in a container that ensures its physical and chemical stability.
The present invention relates to an oral applicable therapeutic dosage form, in particular an orodispersible film comprising Enalapril or pharmaceutically acceptable salts thereof for use in the treatment of hypertension in a pediatric population. The pediatric population is defined from 1 to 18 years of age. The present invention also provides a method of manufacturing of such a dosage form.
The present invention relates to a pediatric chewable tablet comprising a therapeutically effective amount of an antiviral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendly product. It also relates to a process for the preparation thereof.
The present invention relates to water dispersible mini-tablets of Enalapril or a pharmaceutically acceptable salt thereof for use in the treatment of hypertension in a pediatric formulation. The pediatric formulation is defined as 0 to 18 years of age. The present invention also provides a method of manufacturing of such dosage form.
The present invention relates to a pediatric powder for reconstitution as suspension for oral administration comprising a therapeutically effective amount of an antiviral agent or pharmaceutical acceptable salt or derivative thereof, in particular Valaciclovir in complex with an ion exchange resin in a specific ratio in order to obtain a palatable and child-friendly product. It also relates to a process for the preparation thereof.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Generic pharmaceutical preparation for the treatment of gout; Generic pharmaceutical preparations acting on the central nervous system; Generic pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Generic pharmaceutical preparations for animal skincare; Generic pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Generic pharmaceutical preparations for ocular or intraocular surgery; Generic pharmaceutical preparations for the treatment of heart rhythm disorders; Generic pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Generic pharmaceutical preparations for the treatment of infectious diseases; Generic pharmaceutical preparations for treating allergic rhinitis and asthma; Generic pharmaceutical preparations for treating diabetes; Generic pharmaceutical preparations for treating skin disorders; Generic pharmaceutical preparations for use in chemotherapy; Generic pharmaceutical preparations for use in dermatology; Generic pharmaceutical preparations for use in urology; Generic pharmaceutical preparations for wounds; Generic pharmaceutical preparations, namely, anticoagulants; Generic pharmaceutical preparations, namely, antidepressants; Generic pharmaceutical preparations, namely, appetite suppressants. Generic pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Generic pharmaceutical preparations, namely, a drug delivery system comprising polymerbased oral tablets for the continuous release of a wide variety of therapeutic agents; Preparations for destroying parasites; Preparations for destroying vermin; Sanitary preparations for medical use; Self adhesive dressings; Veterinary preparations, namely, pain relief medication Providing advertising, marketing and promotional services for the generic pharmaceutical and medical industry. Providing advertising, marketing and promotional services for the generic pharmaceuticals and medical products of others; Providing information on the topic of promoting patient, physician and employee satisfaction via a global computer network Education services, namely, mentoring in the field of generic pharmaceuticals, diagnostic preparations, veterinary preparations, proprietary medicines, toiletries and cosmetics; Educational services, namely, providing classes, seminars and workshops in the fields of generic pharmaceuticals, diagnostic preparations, veterinary preparations, proprietary medicines, toiletries and cosmetic industries; Providing continuing medical education courses Medical and scientific research services in the field of cancer treatment and diagnosis; Generic pharmaceutical drug development services; generic Pharmaceutical research services; Professional consulting services and advice about agricultural chemistry; Scientific consulting and research services relating to foods and dietary supplements; Technical consultancy in relation to research services relating to foods and dietary supplements; Scientific investigations for medical purposes in the field of generic pharmaceuticals; Scientific research in the field of generic pharmaceuticals; Scientific research and development in the field of generic pharmaceuticals Medical services; Providing health care information by telephone; Providing health care information by telephone and the Internet; Providing health information; Providing information about beauty; Providing medical information, consultancy and advisory services in the field of generic pharmaceuticals; Veterinary services
05 - Produits pharmaceutiques, vétérinaires et hygièniques
35 - Publicité; Affaires commerciales
41 - Éducation, divertissements, activités sportives et culturelles
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Generic pharmaceutical preparation for the treatment of gout; Generic pharmaceutical preparations acting on the central nervous system; Generic pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; Generic pharmaceutical preparations for animal skincare; Generic pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; Generic pharmaceutical preparations for ocular or intraocular surgery; Generic pharmaceutical preparations for the treatment of heart rhythm disorders; Generic pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; Generic pharmaceutical preparations for the treatment of infectious diseases; Generic pharmaceutical preparations for treating allergic rhinitis and asthma; Generic pharmaceutical preparations for treating diabetes; Generic pharmaceutical preparations for treating skin disorders; Generic pharmaceutical preparations for use in chemotherapy; Generic pharmaceutical preparations for use in dermatology; Generic pharmaceutical preparations for use in urology; Generic pharmaceutical preparations for wounds; Generic pharmaceutical preparations, namely, anticoagulants; Generic pharmaceutical preparations, namely, antidepressants; Generic pharmaceutical preparations, namely, appetite suppressants. Generic pharmaceutical preparations, namely, a blood clotting aid and delivery system for use in human and veterinary medicine; Generic pharmaceutical preparations, namely, a drug delivery system comprising polymerbased oral tablets for the continuous release of a wide variety of therapeutic agents; Preparations for destroying parasites; Preparations for destroying vermin; Sanitary preparations for medical use; Self adhesive dressings; Veterinary preparations, namely, pain relief medication Providing advertising, marketing and promotional services for the generic pharmaceutical and medical industry. Providing advertising, marketing and promotional services for the generic pharmaceuticals and medical products of others; Providing information on the topic of promoting patient, physician and employee satisfaction via a global computer network Education services, namely, mentoring in the field of generic pharmaceuticals, diagnostic preparations, veterinary preparations, proprietary medicines, toiletries and cosmetics; Educational services, namely, providing classes, seminars and workshops in the fields of generic pharmaceuticals, diagnostic preparations, veterinary preparations, proprietary medicines, toiletries and cosmetic industries; Providing continuing medical education courses Medical and scientific research services in the field of cancer treatment and diagnosis; Generic pharmaceutical drug development services; generic Pharmaceutical research services; Professional consulting services and advice about agricultural chemistry; Scientific consulting and research services relating to foods and dietary supplements; Technical consultancy in relation to research services relating to foods and dietary supplements; Scientific investigations for medical purposes in the field of generic pharmaceuticals; Scientific research in the field of generic pharmaceuticals; Scientific research and development in the field of generic pharmaceuticals Medical services; Providing health care information by telephone; Providing health care information by telephone and the Internet; Providing health information; Providing information about beauty; Providing medical information, consultancy and advisory services in the field of generic pharmaceuticals; Veterinary services
79.
PHARMACEUTICAL COMPOSITION COMPRISING A TRIAZOLE ANTIFUNGAL AGENT AND METHOD FOR PREPARATION THEREOF
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a therapeutically effective amount of a triazole antifungal agent or pharmaceutical acceptable salt thereof, in particular Voriconazole and an effective amount of a solubility enhancing agent. It also relates to a process for the preparation thereof.
The present invention relates to the implementation of a new method for manufacturing solid dosage forms for oral administration comprising poorly water soluble active ingredients which overcomes the associated solubility problems and affords improved dissolution profile.
A61K 31/40 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil
A61K 31/4535 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un hétérocycle avec le soufre comme hétéro-atome du cycle, p. ex. pizotifène
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
A novel process for the preparation of a long acting injectable composition based on biodegradable poly(D,L-lactide-co-glycolide) microspheres comprising peptide active pharmaceutical ingredients.
The present invention relates to a stable pharmaceutical formulation of solid dosage forms for oral administration comprising a combination of a therapeutically effective amount of a N-containing bisphosphonate, in particular Alendronate or pharmaceutical acceptable salt, derivative or hydrate thereof and Cholecalciferol, which is free of colloidal silicon dioxide and is prepared by dry granulation process in order to inhibit Cholecalciferol degradation.
The present invention relates to an immediate release tablet composition comprising an atypical antipsychotic agent such as Aripiprazole or a pharmaceutical acceptable salt thereof as the active ingredient and an effective amount of at least one pharmaceutically acceptable water soluble and at least one water insoluble diluent. It also relates to a process for the preparation thereof.
The present invention relates to a fast dissolving tablet comprising a therapeutically effective amount of a phosphate binding polymer, such as sevelamer or pharmaceutically acceptable salt or derivative thereof, that exhibit limited swelling in the oral cavity, has pleasant taste and mouth feel, high phosphate binding capacity with fast binding kinetics and require limited amount of water intake. A process for the preparation thereof is disclosed.
The present invention relates to a preservative-free, aqueous solution in the form of eye drops packed in a container that ensures stability of the product, ideal eye drop volume and reduced drop volume variability and provides efficient dispensing.
A61K 47/10 - AlcoolsPhénolsLeurs sels, p. ex. glycérolPolyéthylène glycols [PEG]PoloxamèresAlkyléthers de PEG/POE
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
A61K 31/165 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide
A61K 31/382 - Composés hétérocycliques ayant le soufre comme hétéro-atome d'un cycle ayant des cycles à six chaînons, p. ex. thioxanthènes
C07D 473/18 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'oxygène, de soufre ou d'azote liés directement en positions 2 et 6 un atome d'oxygène et un atome d'azote, p. ex. guanine
C07F 7/18 - Composés comportant une ou plusieurs liaisons C—Si ainsi qu'une ou plusieurs liaisons C—O—Si
87.
A NOVEL PROCESS FOR THE PREPARATION OF CHIRAL CYCLOPENTANONE INTERMEDIATES
C07D 261/20 - Composés hétérocycliques contenant des cycles oxazole-1, 2 ou oxazole-1, 2 hydrogéné condensés avec des carbocycles ou avec des systèmes carbocycliques
C07C 251/40 - Oximes avec des atomes d'oxygène de groupes oxyimino liés à des atomes d'hydrogène ou à des atomes de carbone de radicaux hydrocarbonés non substitués avec les atomes de carbone des groupes oxyimino liés à des atomes d'hydrogène ou à des atomes de carbone acycliques à des atomes de carbone d'un squelette carboné non saturé
C07F 7/18 - Composés comportant une ou plusieurs liaisons C—Si ainsi qu'une ou plusieurs liaisons C—O—Si
C07D 473/18 - Composés hétérocycliques contenant des systèmes cycliques purine avec des atomes d'oxygène, de soufre ou d'azote liés directement en positions 2 et 6 un atome d'oxygène et un atome d'azote, p. ex. guanine
88.
NOVEL PROCESS FOR THE PREPARATION OF EZETIMIBE INTERMEDIATES
C07C 29/143 - Préparation de composés comportant des groupes hydroxyle ou O-métal liés à un atome de carbone ne faisant pas partie d'un cycle aromatique à six chaînons par réduction d'un groupe fonctionnel contenant de l'oxygène de groupes contenant C=O, p. ex. —COOH de cétones
The present invention relates to a novel preparation method for 2-(3-cyano-4-isobutoxyphenyl)- 4-methyl-1,3-thiazole-5-carboxylic acid (Febuxostat) via novel and high yielded conversion of a formyl group in to a cyano group.
The present invention relates to a novel process for the preparation of tetralin and naphthalene derivatives of formula (IV), including Agomelatine and pharmaceutical acceptable salts thereof. Such compounds are considered to be interesting either as useful building blocks or due to their biological activity. The compounds of formula (IV) are prepared from compounds of formula (I) via intermediates (III) by allylic rearrangement.
C07C 233/18 - Amides d'acides carboxyliques ayant des atomes de carbone de groupes carboxamide liés à des atomes d'hydrogène ou à des atomes de carbone acycliques ayant l'atome d'azote d'au moins un des groupes carboxamide lié à un atome de carbone d'un radical hydrocarboné substitué par des atomes d'oxygène liés par des liaisons simples avec le radical hydrocarboné substitué lié à l'atome d'azote du groupe carboxamide par un atome de carbone acyclique ayant l'atome de carbone du groupe carboxamide lié à un atome d'hydrogène ou à un atome de carbone d'un squelette carboné acyclique saturé
C07C 41/18 - Préparation d'éthers par des réactions ne formant pas de liaisons sur l'oxygène de la fonction éther
C07C 41/22 - Préparation d'éthers par des réactions ne formant pas de liaisons sur l'oxygène de la fonction éther par introduction d'atomes d'halogènePréparation d'éthers par des réactions ne formant pas de liaisons sur l'oxygène de la fonction éther par substitution d'atomes d'halogène par des atomes d'autres halogènes
C07C 43/247 - Éthers l'atome d'oxygène de la fonction éther étant lié à un atome de carbone d'un cycle aromatique à six chaînons et à un atome de carbone d'un cycle autre qu'un cycle aromatique à six chaînons contenant des atomes d'halogène
92.
PREPARATION OF POLYLACTIDE-POLYGLYCOLIDE MICROPARTICLES HAVING A SIGMOIDAL RELEASE PROFILE
The present invention relates to preparation of biodegradable microparticles formed from polylactide-polyglycolide copolymers (PLGA) polymer and how to achieve sigmoidal release of active pharmaceutical compound from the microparticles. In particular, the present invention relates to emulsification of an inner/oil phase to an outer/water phase followed by quenching and a single drying step for the preparation of microparticles having a preferred release profile of, preferably basic/nucleophilic compounds such as risperidone. Alternatively the present invention is also suitable for hydrophobic compounds that have poor water-solubility and a high drug loading of >20%w/w is required. The release profile can be controlled by adjusting the degree of saturation of the outer/water phase with the organic solvent used in the inner/oil phase, the polymer concentration of the inner/oil phase and the temperature at the quenching step. In particular, an initial lag phase and a substantially sigmoidal release profile are achieved by using an outer aqueous phase over saturated with the solvent used in the inner phase at emulsification step, in combination with a low temperature during quenching.
The present invention relates to pharmaceutical compositions for parenteral administration comprising Voriconazole or pharmaceutical acceptable salt thereof as the active ingredient and a solubilizing agent such as hydroxypropyl beta cyclodextrin in order to achieve increased solubility of the active ingredient. The present invention also provides a method of preparation of such composition.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
94.
PHARMACEUTICAL COMPOSITION COMPRISING AN ATYPICAL ANTIPSYCHOTIC AGENT AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to orally dispersible pharmaceutical composition comprising an atypical antipsychotic agent such as Aripiprazole or a pharmaceutical acceptable salt thereof as the active ingredient and an effective amount of at least one pharmaceutically acceptable water soluble and at least one water insoluble diluent. It also relates to a process for the preparation thereof.
The present invention relates to a stable pharmaceutical formulation for oral administration comprising a therapeutically effective amount of a serotonin-norepinephrine reuptake inhibitor or a pharmaceutically acceptable salt thereof, in particular Duloxetine that inhibits degradation and/or hydrolysis of the active ingredient. It also relates to a process for the preparation thereof.
The present invention relates to a stable pharmaceutical formulation for oral administration comprising a therapeutically effective amount of fluoroquinolone antibiotic or a pharmaceutically acceptable salt thereof. It also relates to a process for the preparation thereof.
05 - Produits pharmaceutiques, vétérinaires et hygièniques
42 - Services scientifiques, technologiques et industriels, recherche et conception
44 - Services médicaux, services vétérinaires, soins d'hygiène et de beauté; services d'agriculture, d'horticulture et de sylviculture.
Produits et services
Dental preparations and articles; Dietary supplements and dietetic preparations; Pest control preparations and articles. Science and technology services; Medical and pharmacological research services; Design services; IT services; Testing, authentication and quality control. Agriculture, aquaculture, horticulture and forestry services; Animal grooming services; Animal healthcare services; Human healthcare services; Human hygiene and beauty care.
98.
PHARMACEUTICAL COMPOSITION CONTAINING AN OXAZOLIDINONE ANTIBACTERIAL AGENT AND METHOD FOR THE PREPARATION THEREOF
The present invention relates to a solid dosage form for oral administration comprising a therapeutically effective amount of an oxazolidinone antibacterial agent, in particular Linezolid, having D90<75 μm and exhibiting physical and chemical stability. It also relates to a process for the preparation thereof.
The present invention relates to an aqueous pharmaceutical formulation of Moxifloxacin or a pharmaceutically acceptable salt thereof and propylene glycol to be used for the treatment of infections in humans or animals. The present invention also provides a method of preparation of such formulation.
The present invention relates to a stable pharmaceutical composition for sublingual administration comprising a therapeutically effective quantity of an antihistamine agent, in particular Dimenhydnnate and a process for the preparation thereof.
